|
|
News Breaks | | | | January 22, 2013 | | 08:55 EDT |  | CTIC, CTIC, CTIC | Cell Therapeutics to host analyst and investor meeting
Analyst and Investor Meeting to be held in New York on January 23 at 9 am. Webcast Link | |
|
News For CTIC From The Last 14 Days Check below for free stories on CTIC the last two weeks. |
|
|
| June 17, 2013 | | 05:48 EDT |  | CTIC | Cell Therapeutics announces new data from Phase 1, 2 studies of pacritinib
 Subscribe for More Information | | | 05:41 EDT | | CTIC | Cell Therapeutics announces Phase 3 EXTEND results for Pixuvri
Cell Therapeutics announced results from sub-set analyses of data from the Phase 3 EXTEND, or PIX301, clinical trial of Pixuvri. The analyses evaluated the efficacy of Pixuvri in the subset of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, as confirmed by central independent pathological review, who had failed 2 or 3 prior treatment regimens. Compared to physicians' choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30% of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 months with 67% of patients surviving at 2 years. In contrast, only 5.6% of patients in the comparator arm achieved an unconfirmed complete response. The benefit of Pixuvri has not be established in patients when used as 5th-line or greater chemotherapy. | | | June 12, 2013 | | 08:47 EDT | | CTIC | Cell Therapeutics management to meet with UBS
Meeting to be held in Europe on June 12 hosted by UBS. | |
|
|
|
|
|
|
